Skip to main content

Oncology

Featured

News
11/17/2026
Emily Estrada
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society...
11/17/2026
Oncology
FDA Approval
11/16/2026
Stephanie Holland
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
Beth Faiman, CNP, PhD
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
John Mascarenhas, MD
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma |...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
C. Ola Landgren, MD, PhD; Naval G. Daver
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream...
11/16/2026
Oncology
Shannon Westin, MD
Videos
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology

Videos

Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
Beth Faiman, CNP, PhD
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
John Mascarenhas, MD
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma |...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
C. Ola Landgren, MD, PhD; Naval G. Daver
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream...
11/16/2026
Oncology
Shannon Westin, MD
Videos
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology

Insights From the ASCO Annual Meeting

News
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Shannon Westin, MD
Videos
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology
Nikhil Khushalani, MD
Videos
11/12/2026
Nikhil Khushalani, MD
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD,...
11/12/2026
Oncology
Jacob Sands, MD
Videos
11/12/2026
Jacob Sands, MD
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the...
11/12/2026
Oncology
Sara Hurvitz, MD
Videos
11/11/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses...
11/11/2026
Oncology
Benjamin Garmezy, MD
Videos
11/11/2026
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses...
11/11/2026
Oncology
Nilofer Azad, MD
Videos
11/11/2026
Nilofer Azad, MD
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses...
11/11/2026
Oncology
Matteo S. Carlino, MD
Videos
11/11/2026
Matteo Carlino, MD
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses...
11/11/2026
Oncology
Jaafar Bennouna, MD, PhD
Videos
11/10/2026
Jaafar Bennouna, MD, PhD
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD,...
11/10/2026
Oncology
Daniel Heng, MD
Videos
11/09/2026
Daniel Heng, MD
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses...
11/09/2026
Oncology

Live Meetings